The cotyloid fossa fat pad as a hip-specific orthobiologic niche: lessons from the infrapatellar fat pad for mesenchymal stem/stromal cell and extracellular vesicle therapy in osteoarthritis
- 1Department of Orthopaedics, UHealth Sports Medicine Institute, Miller School of Medicine, University of Miami, Miami, FL, United States
- 2Diabetes Research Institute and Cell Transplant Center, Miller School of Medicine, University of Miami, Miami, FL, United States
Abstract
Hip osteoarthritis (OA) is a leading cause of pain and disability worldwide, yet no validated disease-modifying orthobiologic therapy currently exists for the hip joint. The infrapatellar fat pad (IFP) has emerged as a well-characterized intra-articular adipose-synovial niche in the knee, serving as an accessible source of mesenchymal stem/stromal cells (MSC) with robust immunomodulatory, anti-fibrotic, and chondroprotective properties. IFP-MSC have been extensively characterized through surface immunophenotyping, clonogenic assays, secretome profiling, and multilineage differentiation studies, and their therapeutic capacity has been substantially enhanced through cytokine-based, hypoxic, and hormonal priming paradigms. Their derived extracellular vesicles (EV) further extend this therapeutic framework through paracrine immunomodulation, macrophage polarization, and engineered cargo delivery. The cotyloid fossa fat pad (CFFP), an anatomically analogous adipose-synovial structure within the acetabular fossa of the hip, has received comparatively little biological characterization despite its proximity to the acetabular cartilage, labrum, and ligamentum teres. In this review, we use the well-characterized IFP/synovium complex as a reference framework to systematically evaluate what is established and what remains undefined about the CFFP/pulvinar region in the context of hip OA pathogenesis and cell-based therapy. We synthesize evidence across joint pathology, cellular and molecular composition, synovial interactions, immunometabolic phenotype, and translational readiness. Our review revealed a consistent asymmetry in which the IFP reflects an established and growing evidence base while the CFFP has received limited but emerging direct characterization, with its MSC potency, priming responses, and EV function still undefined. We conclude that the IFP/CFFP comparison is scientifically testable and clinically compelling, but that CFFP-MSC and CFFP-EV cannot yet be presented as validated hip-specific orthobiologic candidates until foundational characterization and head-to-head functional comparisons have been completed.
Related
- The infrapatellar fat pad–synovium immunometabolic interface in knee osteoarthritis: a local amplifier of joint inflammation
- TGFB1-Engineered Induced Mesenchymal Stromal Cells Exhibit High Immunomodulatory Potency and Durably Reprogram Synovial Macrophages in Osteoarthritis
- HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice
- Small extracellular vesicle-enriched preparations derived from genetically modified multipotent mesenchymal stromal cells promote fibroblast proliferation and extracellular matrix remodeling in vitro
- Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells
BibTeX
@article{rossow2026cotyloid,
title = {{The cotyloid fossa fat pad as a hip-specific orthobiologic niche: lessons from the infrapatellar fat pad for mesenchymal stem/stromal cell and extracellular vesicle therapy in osteoarthritis}},
author = {R. P. Rossow and R. P. Rossow and K. Polavarapu and K. Polavarapu and M. Naik and M. Naik and L. D. Kaplan and T. M. Best and M. G. Rizzo and D. Kouroupis and D. Kouroupis},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
month = oct,
doi = {10.3389/fbioe.2026.1930127},
url = {https://doi.org/10.3389/fbioe.2026.1930127},
note = {CC BY},
}
RIS
TY - JOUR
TI - The cotyloid fossa fat pad as a hip-specific orthobiologic niche: lessons from the infrapatellar fat pad for mesenchymal stem/stromal cell and extracellular vesicle therapy in osteoarthritis
AU - R. P. Rossow
AU - R. P. Rossow
AU - K. Polavarapu
AU - K. Polavarapu
AU - M. Naik
AU - M. Naik
AU - L. D. Kaplan
AU - T. M. Best
AU - M. G. Rizzo
AU - D. Kouroupis
AU - D. Kouroupis
PY - 2026
DA - 2026/10/28
JO - Frontiers in Bioengineering and Biotechnology
DO - 10.3389/fbioe.2026.1930127
UR - https://doi.org/10.3389/fbioe.2026.1930127
AB - Hip osteoarthritis (OA) is a leading cause of pain and disability worldwide, yet no validated disease-modifying orthobiologic therapy currently exists for the hip joint. The infrapatellar fat pad (IFP) has emerged as a well-characterized intra-articular adipose-synovial niche in the knee, serving as an accessible source of mesenchymal stem/stromal cells (MSC) with robust immunomodulatory, anti-fibrotic, and chondroprotective properties. IFP-MSC have been extensively characterized through surface immunophenotyping, clonogenic assays, secretome profiling, and multilineage differentiation studies, and their therapeutic capacity has been substantially enhanced through cytokine-based, hypoxic, and hormonal priming paradigms. Their derived extracellular vesicles (EV) further extend this therapeutic framework through paracrine immunomodulation, macrophage polarization, and engineered cargo delivery. The cotyloid fossa fat pad (CFFP), an anatomically analogous adipose-synovial structure within the acetabular fossa of the hip, has received comparatively little biological characterization despite its proximity to the acetabular cartilage, labrum, and ligamentum teres. In this review, we use the well-characterized IFP/synovium complex as a reference framework to systematically evaluate what is established and what remains undefined about the CFFP/pulvinar region in the context of hip OA pathogenesis and cell-based therapy. We synthesize evidence across joint pathology, cellular and molecular composition, synovial interactions, immunometabolic phenotype, and translational readiness. Our review revealed a consistent asymmetry in which the IFP reflects an established and growing evidence base while the CFFP has received limited but emerging direct characterization, with its MSC potency, priming responses, and EV function still undefined. We conclude that the IFP/CFFP comparison is scientifically testable and clinically compelling, but that CFFP-MSC and CFFP-EV cannot yet be presented as validated hip-specific orthobiologic candidates until foundational characterization and head-to-head functional comparisons have been completed.
SN - 2296-4185
ER -